Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873283 | 0.89 | EPHX2 (1.00) | EPHX2SMN1; SMN2KMT2ARAB9ANPC1 | |
| SCHEMBL25994389 | 0.86 | EPHX2 (0.71) | EPHX2SMN1; SMN2KMT2ARAB9ANPC1 | |
| SCHEMBL4558228 | 0.84 | EPHX2 (0.91) | EPHX2SMN1; SMN2CYP2C9CYP2C19ACHE | |
| SCHEMBL14413342 | 0.81 | SMN1; SMN2 (0.72) | EPHX2SMN1; SMN2KMT2ARAB9ANPC1 | |
| SCHEMBL12668376 | 0.81 | SMN1; SMN2 (0.77) | EPHX2SMN1; SMN2KMT2ARAB9ANPC1 | |
| SCHEMBL5195426 | 0.78 | SMN1; SMN2 (1.00) | EPHX2SMN1; SMN2KMT2ARAB9ANPC1 | |
| SCHEMBL6153200 | 0.78 | KMT2A (0.69) | EPHX2SMN1; SMN2KMT2ARAB9ANPC1 | |
| SCHEMBL13873287 | 0.77 | EPHX2 (0.77) | EPHX2SMN1; SMN2CYP2C9CYP2C19ACHE | |
| SCHEMBL2093466 | 0.76 | EPHX2 (0.76) | EPHX2SMN1; SMN2CYP2C9CYP2C19ACHE | |
| SCHEMBL14306236 | 0.76 | MAPT (0.69) | EPHX2SMN1; SMN2KMT2ARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | CASP6, CASP1, CASP10 | EPHX2 3551/4885SMN1; SMN2 1519/4885KMT2A 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.